Pages that link to "Q27014888"
Jump to navigation
Jump to search
The following pages link to NKG2D ligands as therapeutic targets (Q27014888):
Displaying 50 items.
- Regulation of Natural Killer Cell Function by STAT3 (Q26752551) (← links)
- Glycosyl-Phosphatidyl-Inositol (GPI)-Anchors and Metalloproteases: Their Roles in the Regulation of Exosome Composition and NKG2D-Mediated Immune Recognition (Q28076151) (← links)
- NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice (Q30277911) (← links)
- NKG2D CARs as cell therapy for cancer (Q33595873) (← links)
- MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. (Q33639723) (← links)
- Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells (Q33676231) (← links)
- NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus (Q33682274) (← links)
- Autonomous stimulation of cancer cell plasticity by the human NKG2D lymphocyte receptor coexpressed with its ligands on cancer cells (Q34301698) (← links)
- Combination cancer immunotherapy and new immunomodulatory targets (Q34487698) (← links)
- Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles. (Q35168522) (← links)
- NKG2D Receptor and Its Ligands in Host Defense (Q35687826) (← links)
- NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT (Q35692428) (← links)
- Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge (Q35783394) (← links)
- Increased Bacterial Load and Expression of Antimicrobial Peptides in Skin of Barrier-Deficient Mice with Reduced Cancer Susceptibility (Q35893302) (← links)
- Autoantibody Profiles in Collagen Disease Patients with Interstitial Lung Disease (ILD): Antibodies to Major Histocompatibility Complex Class I-Related Chain A (MICA) as Markers of ILD. (Q35962818) (← links)
- Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study (Q36211604) (← links)
- Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells (Q36212699) (← links)
- The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB. (Q36723387) (← links)
- VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer (Q37086056) (← links)
- Expression of the inhibitory Ly49E receptor is not critically involved in the immune response against cutaneous, pulmonary or liver tumours. (Q37137278) (← links)
- NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline (Q37316220) (← links)
- The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma (Q37622429) (← links)
- The anti-tumor role of NK cells in vivo pre-activated and re-stimulated by interleukins in acute lymphoblastic leukemia (Q37694772) (← links)
- Cell transfer therapy for cancer: past, present, and future (Q38205228) (← links)
- MICA SNPs and the NKG2D system in virus-induced HCC. (Q38255751) (← links)
- Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma. (Q38376092) (← links)
- Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease (Q38460376) (← links)
- Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels (Q38634034) (← links)
- NK cells and cancer: you can teach innate cells new tricks. (Q38676458) (← links)
- Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion (Q38706890) (← links)
- Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. (Q38730881) (← links)
- Role of NKG2D in cytokine-induced killer cells against lung cancer (Q38772095) (← links)
- CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies (Q38783833) (← links)
- NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors. (Q38788557) (← links)
- How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy (Q38830813) (← links)
- Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors (Q38860610) (← links)
- Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them (Q38987239) (← links)
- Cellular and vaccine immunotherapy for multiple myeloma. (Q39027834) (← links)
- Intercellular Communication of Tumor Cells and Immune Cells after Exposure to Different Ionizing Radiation Qualities (Q39389306) (← links)
- Assessment of changes in expression and presentation of NKG2D under influence of MICA serum factor in different stages of breast cancer. (Q40216461) (← links)
- Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells. (Q40348935) (← links)
- Downregulation of the stress-induced ligand ULBP1 following SV40 infection confers viral evasion from NK cell cytotoxicity (Q40749737) (← links)
- Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition (Q41367801) (← links)
- Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia (Q41558781) (← links)
- Anti-NKG2D mAb: A New Treatment for Crohn's Disease? (Q41660377) (← links)
- Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway (Q44243898) (← links)
- p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. (Q45160655) (← links)
- Natural Killer Cell Interactions with Classical and Non-Classical Human Leukocyte Antigen Class I in HIV-1 Infection (Q46722989) (← links)
- Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors (Q47114951) (← links)
- Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types (Q47159409) (← links)